|
RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis. |
|
|
Research Funding - Bristol-Myers Squibb; Lilly; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
Honoraria - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb; Lilly |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst) |
|
|
Research Funding - Daiichi Sankyo; Lilly; Roche; Sanofi; Taiho Pharmaceutical |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |